Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Exelixis, Inc. - Common Stock
(NQ:
EXEL
)
56.13
+1.07 (+1.95%)
Streaming Delayed Price
Updated: 3:44 PM EDT, Aug 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis, Inc. - Common Stock
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
December 08, 2022
From
Exelixis, Inc.
Via
Business Wire
3 Stocks to Buy Hand Over Fist in December
↗
December 03, 2022
These stocks could be big winners.
Via
The Motley Fool
What 4 Analyst Ratings Have To Say About Exelixis
↗
November 02, 2022
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Exelixis Inks Two Licensing Pacts For Cancer Programs
↗
November 02, 2022
Via
Benzinga
Exelixis (EXEL) Q3 2022 Earnings Call Transcript
↗
November 02, 2022
EXEL earnings call for the period ending September 30, 2022.
Via
The Motley Fool
Exelixis to Present at the Virtual JMP Securities Hematology and Oncology Summit on December 7, 2022
November 30, 2022
From
Exelixis, Inc.
Via
Business Wire
Nasdaq Bear Market: 3 Surefire Growth Stocks to Buy to End the Year Right
↗
November 30, 2022
Investors can end the year on a high note by scooping up shares of these bargain-basement-priced growth stocks.
Via
The Motley Fool
The Smartest Stocks to Buy With $20 Right Now
↗
November 16, 2022
You don't need a mountain of cash to begin building wealth on Wall Street.
Via
The Motley Fool
2 No-Brainer Stocks to Buy Right Now for Less than $20
↗
November 12, 2022
These stocks are still bargain-priced but benefit from long-term trends.
Via
The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November
November 10, 2022
From
Exelixis, Inc.
Via
Business Wire
Here's Why This Growth Stock Is Already My 2022 Winner
↗
November 09, 2022
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.
Via
The Motley Fool
Looking Into Exelixis's Return On Invested Capital
↗
November 08, 2022
Pulled from Benzinga Pro data, Exelixis (NASDAQ:EXEL) posted Q3 earnings of $73.21 million, an increase from Q2 of 3.59%. Sales dropped to $411.74 million, a 1.83% decrease between quarters.
Via
Benzinga
Exelixis and Catalent Enter into New License Agreement for Three Antibody-Drug Conjugate Programs with the Potential to Accelerate Exelixis’ Biologics Pipeline
November 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis and Sairopa Establish Exclusive Clinical Development Collaboration and Option Agreement to Develop ADU-1805, a Potentially Best-in-Class Monoclonal Antibody Targeting SIRPα
November 01, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis and Cybrexa Therapeutics Establish Exclusive Collaboration Providing Exelixis the Right to Acquire CBX-12, a Potential First-in-Class Peptide-Drug Conjugate of Exatecan
November 01, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Third Quarter 2022 Financial Results and Provides Corporate Update
November 01, 2022
From
Exelixis, Inc.
Via
Business Wire
Nasdaq Bear Market: 5 Magnificent Growth Stocks You'll Regret Not Buying on the Dip
↗
October 29, 2022
With the Nasdaq Composite down as much as 38% from its peak, these highly innovative companies are ripe for the picking.
Via
The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022
↗
November 01, 2022
Upgrades
Via
Benzinga
2 Top Biotech Stocks to Buy for the Long Haul
↗
October 28, 2022
Both drugmakers have outperformed the market in the past year.
Via
The Motley Fool
Exelixis Announces Promising Initial Dose-Escalation Results from the First-in-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022
October 26, 2022
From
Exelixis, Inc.
Via
Business Wire
Worried About Rising Interest Rates? These 2 Growth Stocks Could Offer a Solution
↗
October 19, 2022
These stocks have low-to-no debt, and analysts see tons of upside.
Via
The Motley Fool
Exelixis to Release Third Quarter 2022 Financial Results on Tuesday, November 1, 2022
October 18, 2022
From
Exelixis, Inc.
Via
Business Wire
The Smartest Stocks to Buy With $20 Right Now
↗
October 14, 2022
Cheap stocks have the ability to generate enormous, long-term profits for investors.
Via
The Motley Fool
These 7 Biotech Stocks Are Set to Boom in 2023
↗
October 10, 2022
This article looks at seven biotech stocks that look like good options to move significantly higher in 2023
Via
InvestorPlace
Exelixis Expands Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Include the Fixed-Dose Combination of Nivolumab and Relatlimab in Combination with XL092 in Phase 1b STELLAR-002 Trial
October 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022
↗
October 18, 2022
Upgrades
Via
Benzinga
3 Biotech Stocks to Buy Now for Extraordinary Gains
↗
September 20, 2022
These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.
Via
InvestorPlace
Exelixis' XL092/ Atezolizumab Shows Encouraging Efficacy, Safety In Heavily Pretreated Cancer Patients
↗
September 12, 2022
Via
Benzinga
Exelixis Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022
September 10, 2022
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
...
16
17
18
19
20
21
22
23
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
